A new drug in treatment of severe alopecia areata in adolescents and adults:Ritlecitinib
10.13699/j.cnki.1001-6821.2024.01.026
- VernacularTitle:治疗青少年和成人重度斑秃新药:Ritlecitinib
- Author:
Ming-Ming ZHANG
1
;
Bao-Qiang ZHU
;
Shi-Yu YANG
;
Jia-Qiang HU
;
Rong-Sheng TONG
;
En-Wu LONG
Author Information
1. 电子科技大学医学院,四川成都 610054
- Keywords:
Janus kinase inhibitor;
adolescent;
severe alopecia areata;
Ritlecitinib
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(1):126-129
- CountryChina
- Language:Chinese
-
Abstract:
Ritlecitinib is an inhibitor that acts on Janus kinase 3 and the hepatocellular carcinoma kinase family.In June 2023,the FDA approved Ritlecitinib for the treatment of severe alopecia areata in patients aged 12 years and above.Multiple clinical studies have observed hair regeneration in patients after using Ritlecitinib,which is generally safe and well tolerated during use.This article introduces its pharmacological effects,pharmacokinetics,clinical research,safety,and usage and dosage.
